- Providers
- Conference
ASCO® GU Symposium 2023
Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to share our latest scientific and clinical research findings during the ASCO Genitourinary Cancers Symposium 2023.
Pathogenic BRAF K601E Mutations in Prostate Cancer: Frequency and Distribution
BRAF mutations are known to be clinically significant in a variety of cancers. While the prevalence of BRAF p.V600E is well described, the remaining landscape of pathogenic/likely pathogenic (P/LP) BRAF mutations is poorly understood. This study leveraged Tempus’ multimodal dataset to evaluate the prevalence of BRAF P/LP variants in a large-scale cohort of prostate cancer patients.
Elisa Ledet (Tulane University), Elizabeth Mauer (Tempus), Oliver Sartor (Tulane University), et al.
Homologous Recombination Repair (HRR) Mutation Concordance Between Liquid Biopsy (LB) and Tumor Tissue by NGS in a Real-World Prostate Cancer (PC) Database
Utilization of NGS to identify HRR mutations is indicated in advanced prostate cancer. This study used Tempus’ large real-world multimodal database to determine concordance between plasma ctDNA and primary tumor tissue and/or metastatic tissue for BRCA1, BRCA2, and ATM mutations in prostate cancer patients. In addition, these data were used to establish the utility of combined liquid biopsy and tissue testing in this setting.
John Shen (UCLA), Liang Wang (UCLA), Ali Khaki (Stanford), Rafael E. Jimenez (Mayo Clinic), Elizabeth Mauer (Tempus), Manish Kohli (University of Utah), et al.
CDK12 Pathogenic Mutations in African American and White Patients with Prostate Cancer
African American men are underrepresented in prostate cancer trials despite having a greater probability of both developing and dying from prostate cancer. CDK12 mutations in prostate cancer are associated with aggressive disease, increased metastasis, and decreased overall survival. Preliminary data suggests pathogenic CDK12 mutations may be more common in African American men. This study reports real-world NGS data from Tempus’ multimodal database to investigate the frequency of pathogenic CDK12 mutations in African American and White prostate cancer patients.
Oliver Sartor (Tulane University), Elisa Ledet (Tulane University), Nicholas Mitsiades (UC Davis), Ellen Jaeger (Tempus)
Real-World Treatment Patterns and Sequencing in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (LA/MUC) in the US
The 2020 FDA approval of avelumab in locally advanced/metastatic urothelial cancer provided new opportunities for the sequence of treatment approaches. However, little is known about the changes that have occurred in clinical practice since then. Further, treatment sequencing paradigms for these patients still lacks consensus. This study used Tempus real-world data to describe the characteristics and treatment patterns of patients with locally advanced/metastatic urothelial cancer.
Mairead Kearney (Merck), Chiemeka Ike (EMD Serono), Ambar Modh (Tempus), Ken Carson (Rush), et al.
Molecular Characteristics of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) Harboring TERT Mutations
There is a large unmet need for identifying prognostic and predictive biomarkers in advanced renal cell carcinoma (RCC) and Urothelial Carcinoma (UC). This study aimed to utilize Tempus’ multimodal database to analyze the molecular and immune biomarker landscape in TERT mutated versus wild type RCC and UC.
Nataliya Mar (UC Irvine), Arash Rezazadeh (UC Irvine), Arya Ashok (Tempus), Ellen Jaeger (Tempus)
Schedule a meeting with us
We'll be in touch shortly.